The study included 444 stage II-III operable HER2+ BC patients who were randomly assigned to NAT with T-DM1 plus pertuzumab (T-DM1+P) or docetaxel, carboplatin, or trastuzumab plus pertuzumab (TCbHP). The gene discussed is ERBB2; the disease is breast cancer.